JP2008539240A - 持続放出性処方物 - Google Patents

持続放出性処方物 Download PDF

Info

Publication number
JP2008539240A
JP2008539240A JP2008508975A JP2008508975A JP2008539240A JP 2008539240 A JP2008539240 A JP 2008539240A JP 2008508975 A JP2008508975 A JP 2008508975A JP 2008508975 A JP2008508975 A JP 2008508975A JP 2008539240 A JP2008539240 A JP 2008539240A
Authority
JP
Japan
Prior art keywords
sustained release
granules
formulation
mesh
wax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008508975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539240A5 (https=
Inventor
シュブハ チュンギ，
Original Assignee
テバ ファーマシュ−ティカルズ ユーエスエー， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシュ−ティカルズ ユーエスエー， インコーポレイテッド filed Critical テバ ファーマシュ−ティカルズ ユーエスエー， インコーポレイテッド
Publication of JP2008539240A publication Critical patent/JP2008539240A/ja
Publication of JP2008539240A5 publication Critical patent/JP2008539240A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2008508975A 2005-04-25 2006-04-25 持続放出性処方物 Withdrawn JP2008539240A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67444405P 2005-04-25 2005-04-25
PCT/US2006/015373 WO2006116247A1 (en) 2005-04-25 2006-04-25 Extended release formulations

Publications (2)

Publication Number Publication Date
JP2008539240A true JP2008539240A (ja) 2008-11-13
JP2008539240A5 JP2008539240A5 (https=) 2009-05-21

Family

ID=36698750

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008508975A Withdrawn JP2008539240A (ja) 2005-04-25 2006-04-25 持続放出性処方物

Country Status (9)

Country Link
US (1) US20060275367A1 (https=)
EP (1) EP1877040A1 (https=)
JP (1) JP2008539240A (https=)
AU (1) AU2006239838A1 (https=)
BR (1) BRPI0610257A2 (https=)
CA (1) CA2605792A1 (https=)
MX (1) MX2007013327A (https=)
RU (1) RU2007143556A (https=)
WO (1) WO2006116247A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007122636A1 (en) * 2006-04-25 2007-11-01 Panacea Biotec Ltd Pharmaceutical compositions containing long chain fatty acids as excipients as well as a process for manufacturing the same
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
AU2007335156A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
CN102036656A (zh) * 2008-03-21 2011-04-27 米兰制药有限公司 含有蜡的缓释制剂
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
WO2014051443A1 (en) * 2012-09-27 2014-04-03 Mendoza Wendell G Method for producing extended-release potassium citrate wax matrix tablet
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2022266311A1 (en) * 2021-06-16 2022-12-22 Summit Biomedical Imaging PARPi-FL FORMULATIONS
CN117100711A (zh) * 2022-05-16 2023-11-24 江苏万珺医药科技有限公司 一种含有盐酸曲唑酮的缓释片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2489439A (en) * 1947-06-27 1949-11-29 Samuel M Taylor Record controlled printing machine
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
FI894611L (fi) * 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutiska preparat.
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
TW209174B (https=) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
JP2616252B2 (ja) * 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6162466A (en) * 1999-04-15 2000-12-19 Taro Pharmaceutical Industries Ltd. Sustained release formulation of carbamazepine
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
NZ542303A (en) * 2003-03-14 2008-12-24 Nirmal Mulye A process for preparing sustained release tablets
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation

Also Published As

Publication number Publication date
US20060275367A1 (en) 2006-12-07
AU2006239838A1 (en) 2006-11-02
WO2006116247A1 (en) 2006-11-02
BRPI0610257A2 (pt) 2010-06-08
RU2007143556A (ru) 2009-06-10
MX2007013327A (es) 2008-04-21
CA2605792A1 (en) 2006-11-02
EP1877040A1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
US6596308B2 (en) Controlled release pharmaceutical composition
EP3823597A2 (en) Multiparticulate formulations of cannabinoids
KR20100126452A (ko) 난용성 약물용 약학적 조성물
JPS629A (ja) 持続放出性複合単位製剤
PL200957B1 (pl) Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
TW577738B (en) Sustained release pharmaceutical composition
WO1995013794A1 (en) Process for producing stable medicinal composition, and pharmaceutical preparation
TW201019938A (en) Pharmaceutical formulations of an HCV protease inhibitor in a solid molecular dispersion
JP2011516527A (ja) 医薬品有効成分の造粒
JP2008539240A (ja) 持続放出性処方物
WO2022026519A1 (en) Novel gastroretentive extended release dosage form
TW200800178A (en) Pharmaceutical formulations of a monohydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
KR20220112746A (ko) 치료 제형 및 이의 용도
JP2008539231A (ja) 濡れ性の向上した、医薬として許容され得る可塑剤が組み込まれたセルロース系フィルム
TW201016217A (en) Galenical formulations of organic compounds
CN1193754C (zh) 释放控制型口服制剂
WO2007073389A1 (en) Compressed solid dosage forms with drugs of low solubility and process for making the same
US20230167181A1 (en) Pharmaceutical compositions and methods of manufacture using thermally conductive excipients
US11925707B2 (en) Co-processed lubricant:MCG for tablets
EP1784161B1 (en) Controlled-release formulation comprising tamsulosin hydrochloride
WO2024218790A1 (en) A pharmaceutical composition of ubrogepant and their process for the preparation of solid dosage form for treating migraine
CN121175036A (zh) 药物组合物
ES2430333T3 (es) Composiciones de matriz para liberación controlada de principios activos
EP3727345A1 (en) Once-daily formulation of hidrosmin
OA20151A (en) Once-daily formulation of hidrosmin.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090402

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090402

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100604

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20100604

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100607